ORAGENICS INC (OGEN) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US6840236094

Price
0.20 USD
Market cap
906,903.36 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ORAGENICS INC financials

Fiscal year2025
Operating income-9.36 m USD
EBIT-9.38 m USD
Net income-9.84 m USD
Diluted EPS – continuing operations-4.56 USD

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ORAGENICS INC

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.